Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis

Clinical Rheumatology

Volumn 34, Issue 1, 2015, Pages 117-124

  Danve, Abhijeet ^a   Reddy, Anusha ^b   Vakil Gilani, Kiana ^a   Garg, Neha ^a   Dinno, Alexis ^c   Deodhar, Atul ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c PORTLAND STATE UNIVERSITY   (United States)

Author keywords

Ankylosing spondylitis; Axial spondyloarthritis; Bath Ankylosing Spondylitis Disease Activity index (BASDAI); Inflammatory back pain; Routine Assessment of Patient Index Data 3 Scores (RAPID3); Seronegative spondyloarthropathy

Indexed keywords

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; AXIAL SPONDYLOARTHRITIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FIBROMYALGIA; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PATIENT MONITORING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 SCORE; SPONDYLARTHRITIS; CROSS-SECTIONAL STUDY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

ADULT; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 84922105802     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2827-4     Document Type: Article

References (23)

1. Goekoop-Ruiterman YPM, Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146:406–415
2. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269
3. Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M et al (2005) Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 52:36–41
4. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden SJ (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353–358
5. Smolen JS, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P et al (2014) Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73:6–16
6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291
7. Zochling J (2011) Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res 63(Suppl 11):47–58
8. Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T (2007) A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 21:789–804
9. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R (2008) An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 47:345–349
10. Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35:2136–2147
11. Castrejón I, Bergman MJ, Pincus T (2013) MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritis. J Clin Rheumatol 19:169–174
12. van der Linden SM, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
13. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31
14. Pincus T, Swearingen C, Wolfe F (1999) Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 42:2220–2230
15. Pincus T, Sokka T, Kautiainen H (2005) Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol 32:1432–1439
16. van der Heijde DMFM, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden SJEF (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24:2225–2229
17. Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24
18. van der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818
19. Pincus T, Swearingen CJ, Bergman MJ, Colglazier CL, Kaell AT, Kunath AM et al (2010) RAPID3 on an MDHAQ is correlated significantly with activity levels of DAS28 and CDAI, but scored in 5 versus more than 90 seconds. Arthritis Care Res 62:181–189
20. Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F et al (2003) An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20 % response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 48:625–630
21. Pincus T, Chung C, Segurado OG, Amara I, Koch GG (2006) An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 33:2146–2152
22. Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K (2011) RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res 63:1142–1149
23. Kaptanoglu E, Sahin O, Durmaz Y, Cengiz AK, Hizmetli S (2013) Routine Assessment of Patient Index Data 3 in fibromyalgia: a rapid and reliable instrument for evaluating disease severity? Arthritis Rheum 65(Suppl 10):48